ArticleThe journal of allergy and clinical immunology. Global2026
Development of a patient-centered asthma action plan for single maintenance and reliever therapy (MART).
Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- As-needed inhaled corticosteroids in asthma: from evidence to implementation.Current opinion in pulmonary medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent guidelines recommend maintenance and reliever therapy (MART) as the preferred inhaler regimen for patients with moderate to severe asthma. However, updated asthma action plans (AAPs), specifically tailored to MART, have not been developed for the US population. Objective: We sought to design a MART-specific AAP that is accessible, pictorial, and low-burden for clinicians to use during time-constrained clinical encounters. Methods: Together with health communication design experts, we used a multiphase, mixed-methods approach involving semistructured interviews with 7 adult patients with asthma and 6 clinicians at community health centers while exploring preferences for AAP content and design. Thematic analyses informed our design process, which used the 5E Design Thinking Framework. Our team ultimately developed 2 MART-specific AAPs and assessed their readability using a Flesch-Kincaid test. Results: Patients prioritized simple visuals, concise instructions, and clear guidance for managing worsening symptoms as key to a new MART-specific AAP. Clinicians emphasized the importance of time efficiency when completing AAPs. Using this feedback, we developed a 4" × 6" wallet-sized trifold AAP with a Flesch-Kincaid grade level of 3.7 specifically tailored for MART. Conclusions: Because guidelines endorse MART as the preferred asthma therapy, new and updated MART-specific AAPs are important to facilitate optimal asthma care. Our team codesigned 2 MART-specific AAPs based on patient and clinician feedback.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.